The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
N | Nervous system | |
2
|
N03 | Antiepileptics | |
3
|
N03A | Antiepileptics | |
4
|
N03AX | Other antiepileptics | |
5
|
N03AX23 |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Code | Route | Amount | Notes |
|---|---|---|---|
| ORAL | Oral | 0.1 g | |
| PAREN | Parenteral | 0.1 g |
| Active Ingredient |
|---|
|
Brivaracetam displays a high and selective affinity for synaptic vesicle protein 2A (SV2A), a transmembrane glycoprotein found at presynaptic level in neurons and in endocrine cells. Although the exact role of this protein remains to be elucidated it has been shown to modulate exocytosis of neurotransmitters. |
| Document | Type | Information Source | |
|---|---|---|---|
| BRIVIACT Film-coated tablet | MPI, EU: SmPC | European Medicines Agency (EU) | |
| BRIVLERA Tablet, Oral solution, Solution for injection | MPI, CA: SPM | Health Products and Food Branch (CA) |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.